The Company's family of patented monotherapeutic molecules focuses on treating oxidative stress-related diseases, chronic pain management, and neurodegenerative disorders. Kannalife's research has been backed by a total of $3.3 million in grant funding from the National Institutes of Health (NIH) under the NIH HEAL Initiative and focused on the treatment of chemotherapy induced peripheral neuropathy (CIPN). The Neuropathix leadership team has more than 40 years of business, marketing and drug development experience with Fortune 500, Pharma and leading Biotechnology firms.
Cyborg Score Rationale
Neuropathix has promising preclinical science and substantial IP estate with NIH backing, but remains in early-stage development as a micro-cap OTC stock with very limited headcount (2-10 employees). Progress on advancing KLS-13019 toward clinical trials is not yet evident.
Top Insights
Lead compound KLS-13019 reportedly 200X more potent and significantly more bioavailable than CBD, positioning it as potentially superior for neuropathic pain and neurodegenerative indications
Subsidiary Kannalife Sciences holds substantial NIH grant funding ($3.3M) for CIPN research under the NIH HEAL Initiative, validating scientific direction
Micro-cap OTC public company with very small headcount and uncertain commercial execution capabilities
Named Competitors
Gilgamesh Pharmaceuticals — Neuroinflammation and pain therapeutics
Alto Neuroscience — CNS and neurodegeneration therapeutics
4E Therapeutics — Pain and neurological disorder therapeutics
Recent Developments
(2024) KLS-13019 preclinical study conducted in partnership with Michael J. Fox Foundation targeting motor impairment in Parkinson's disease models
(December 2020) Acquired neuroprotective and anticonvulsant IP estate from Advanced Neural Dynamics and Fox Chase Chemical Diversity Center for refractory epilepsy program
Open the full interactive Neuropathix, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.